Piscataway, NJ, July 3, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Ivabradine Tablets to its product line.
Ivabradine Tablets is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
Ivabradine Tablets are available in strengths of 5 and 7.5 mg in 60 count bottles.
To learn more about Ivabradine Tablets, please visit https://www.camberpharma.com/Ivabradine
